Glenmede Trust CO Na Cerus Corp Transaction History

Glenmede Trust CO Na

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$1.5 - $3.07 $15,370 - $31,458	10,247 New	10,247 $16,000
Q2 2021 Aug 16, 2021	SELL	$5.35 - $6.35 $94,486 - $112,147	-17,661 Closed	0 $0
Q1 2021 May 18, 2021	BUY	$5.68 - $7.87 $73 - $102	13 Added 0.07%	17,661 $105,000
Q4 2020 Feb 16, 2021	BUY	$5.25 - $8.56 $1,212 - $1,977	231 Added 1.33%	17,648 $121,000
Q2 2020 Aug 14, 2020	SELL	$4.5 - $7.02 $43,024 - $67,118	-9,561 Reduced 35.44%	17,417 $114,000
Q4 2019 Feb 12, 2020	BUY	$3.84 - $4.86 $2,565 - $3,246	668 Added 2.54%	26,978 $113,000
Q3 2019 Nov 14, 2019	SELL	$4.86 - $6.05 $972 - $1,210	-200 Reduced 0.75%	26,310 $135,000
Q4 2018 Feb 14, 2019	BUY	$4.89 - $7.16 $557 - $816	114 Added 0.43%	26,510 $133,000
Q3 2018 Nov 15, 2018	BUY	$6.89 - $7.78 $1,378 - $1,556	200 Added 0.76%	26,396 $190,000
Q2 2018 Aug 15, 2018	BUY	$5.19 - $7.25 $54,495 - $76,125	10,500 Added 66.9%	26,196 $175,000
Q3 2017 Nov 14, 2017	BUY	$2.22 - $2.73 $34,845 - $42,850	15,696	15,696 $0

156

148M

84.2K

55.5K

Ticker CERS
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 177,090,000
Market Cap $317M
Description
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended fo...

Get notified when there are updates to the investment portfolio of Glenmede Trust CO Na, based on Form 13F filings with the SEC.

Stay updated on Glenmede Trust CO Na with notifications on news.